Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Toward patient-centered drug development in oncology.

Basch E.

N Engl J Med. 2013 Aug 1;369(5):397-400. doi: 10.1056/NEJMp1114649. Epub 2013 Jul 3. No abstract available.

2.

Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval.

Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, Tibes R, Mesa R.

Leuk Lymphoma. 2014 Jan;55(1):195-7. doi: 10.3109/10428194.2013.789507. Epub 2013 Jun 12. No abstract available.

PMID:
23647081
3.

Oncology update.

Smart M.

Oncol Nurs Forum. 2011 Jul;38(4):485-6. doi: 10.1188/11.ONF.485-486. No abstract available.

PMID:
21708539
4.

[Off-label use in oncology. The Italian choice].

Felicetti V, Gremigni U, Cifaldi L.

Recenti Prog Med. 2008 Dec;99(12):612-5. Italian.

PMID:
19388222
5.

Accelerated approval and oncology drug development timelines.

Lanthier ML, Sridhara R, Johnson JR, Farrell A, Keegan P, Justice R, Pazdur R.

J Clin Oncol. 2010 May 10;28(14):e226-7; author reply e228. doi: 10.1200/JCO.2009.26.2121. Epub 2010 Mar 1. No abstract available.

PMID:
20194846
6.

Clinical and outcome research in oncology. The need for integration.

Apolone G.

Health Qual Life Outcomes. 2003 Apr 3;1:3.

7.

Should the FDA be the doctor of last resort?

DeVita VT Jr.

Nat Clin Pract Oncol. 2005 Sep;2(9):423. No abstract available.

PMID:
16264991
8.

Managed care outlook. Oncologists: FDA needs to speed up approval of cancer-fighting drugs.

[No authors listed]

Manag Care. 2002 Jun;11(6):56. No abstract available.

9.

Oncology 2020: a drug development and approval paradigm.

Dhingra K.

Ann Oncol. 2015 Nov;26(11):2347-50. doi: 10.1093/annonc/mdv353. Epub 2015 Sep 15. No abstract available.

PMID:
26374285
10.

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials.

Kumar H, Fojo T, Mailankody S.

JAMA Oncol. 2016 Sep 1;2(9):1238-40. doi: 10.1001/jamaoncol.2016.0931. No abstract available.

PMID:
27281466
11.

The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?

Grillo-López AJ.

Expert Rev Anticancer Ther. 2004 Dec;4(6):941-4. No abstract available.

PMID:
15606323
12.

Better prioritization may speed approval of adjuvant therapies in breast cancer.

Tuma RS.

J Natl Cancer Inst. 2008 Jun 18;100(12):842-4. doi: 10.1093/jnci/djn197. Epub 2008 Jun 10. No abstract available.

PMID:
18544735
13.

Accelerated approval dust begins to settle.

Mullard A.

Nat Rev Drug Discov. 2011 Oct 31;10(11):797-8. doi: 10.1038/nrd3580. No abstract available.

PMID:
22037027
14.

Seamless Oncology-Drug Development.

Prowell TM, Theoret MR, Pazdur R.

N Engl J Med. 2016 May 26;374(21):2001-3. doi: 10.1056/NEJMp1603747. Epub 2016 Apr 13. No abstract available.

15.

The importance of quality-of-life endpoints in clinical trials to the practicing oncologist.

Passik SD, Kirsh KL.

Hematol Oncol Clin North Am. 2000 Aug;14(4):877-86. Review.

PMID:
10949778
16.

Ups and downs at ASCO 2014.

Adams KT.

Manag Care. 2014 Aug;23(8):50-2. No abstract available.

17.

Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.

Pennell NA.

Am J Manag Care. 2012 May;18(5 Spec No. 2):SP84-7. No abstract available.

18.

Response Rate as an Approval End Point in Oncology: Back to the Future.

Blumenthal GM, Pazdur R.

JAMA Oncol. 2016 Jun 1;2(6):780-1. doi: 10.1001/jamaoncol.2015.6352. No abstract available.

PMID:
26913938
19.

Cancer research: does it deliver for the patient?

Oldham RK.

Cancer Biother. 1994 Summer;9(2):99-102. No abstract available.

PMID:
7812366
20.

New office and new leader aim to streamline FDA cancer drug review process.

Twombly R.

J Natl Cancer Inst. 2005 May 18;97(10):708-9. No abstract available.

PMID:
15900036

Supplemental Content

Support Center